[A22-85] Anifrolumab (systemic lupus erythematosus) - Addendum to Commission A22-35
Last updated 06.10.2022
Project no.:
A22-85
Commission:
Commission awarded on 09.08.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Indication:
Add-on treatment in adults with moderate to severe active autoantibody-positive SLE despite standard therapy
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-35 | Anifrolumab (systemic lupus erythematosus) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
06-10-2022 A G-BA decision was published.